Health-related quality of life and associated factors among people living with human immunodeficiency virus on highly active antiretroviral therapy in North East Ethiopia: Cross-sectional study

Solomon Ahmed Mohammed1*, Minilu Girma Yitafr2, Birhanu Demekhe Workneh1, Abel Demerew Hailu3

1 Department of Pharmacy, College of Medicine and Health Science, Wollo University, Dessie, Ethiopia, 2 Department of Pharmacy, College of Medicine and Health Science, Debre Berhan University, Debre Berhan, Ethiopia, 3 Department of Pharmacy, Dessie Health Science College, Dessie, Ethiopia

* ahmedsolomon21@gmail.com

Abstract

Introduction
HIV/AIDS remains a public health concern affecting millions of people across the world. Although the health-related quality of life (HRQoL) of patients living with HIV has significantly improved after treatment, its chronicity makes the HRQoL uncertain. This study assessed factors associated with the health-related quality of life among people living with HIV/AIDS on HAART in North-East Ethiopia.

Methods
An institutional-based cross-sectional study was conducted from March to April 2018, and systematic random sampling was used to select 235 participants who were on HAART. HRQoL was assessed using the Medical Outcomes Study HIV Health Survey. Descriptive and multiple linear regression analysis were computed using the statistical package for social sciences version 20.

Results
The study revealed one-factor structure and had good overall internal consistency (78.5). Over one-third (42.6%; 95% CI; 36.2%, 48.9%) of participants had good HRQoL. The least HRQoL mean score was found for cognitive functioning 32.21(±19.78), followed by social functioning 40.58(±29.8). Factors associated with the overall HRQoL were 25–45 years of age (β = -3.55, 95% CI;-6.54, -0.55), working in private sector (β = -5.66, 95% CI;-9.43, -1.88), government (β = -4.29, 95% CI;-7.83, -0.75) and self-employment (β = -8.86, 95% CI;-13.50, -4.21), 100–200 (β = -4.84, 95% CI;-9.04, -0.63) and 201–350 CD4 at the time of diagnosis (β = -7.45, 95% CI;-11.73, -3.16), 351–500 current CD4 level (β = 8.34, 95%
Conclusions

High proportion of participants had a poor HRQoL. Routine assessment and appropriate interventions at each visit is recommended to improve HRQoL.

Introduction

Human Immunodeficiency Virus (HIV)/ Acquired Immunodeficiency Syndrome (AIDS) is being a global concern, and people of the world are suffering from this problem. Between 1990 and 2015, 34 million people died from AIDS-related causes, where 15–24 years old people comprised about one-third of the people who acquired HIV infection globally [1]. In 2019, 38 million people are living with HIV and 1.7 million people were newly infected. AIDS-related illnesses were responsible for 690,000 people’s death. Nearly 25.4 million people were accessing antiretroviral therapy [2]. Among the newly HIV infections per day, about 61% were in sub-Saharan Africa. In Ethiopia, 23,000 people were newly infected in 2018 [3].

According to the World Health Organization (WHO), quality of life (QoL) is an individual’s perception of their position in life in the context of the culture and value systems in which they live and concerning their goals, expectations, standards, and concerns [4]. When the quality of life is considered in the context of health and disease, it is referred to as health-related quality of life (HRQoL) [5]. Despite several QoL instruments (short form-36 health survey [6], short form-12 [7] and World Health Organization quality of life (WHOQOL)-BREF [8]) that have been used to evaluate HRQoL of HIV-infected patients, each has a distinct feature. Among these, the Medical Outcomes Study HIV Health Survey (MOS-HIV) allows calculation in both individuals scale and summary scores and incorporates three domains (cognitive functioning, health distress, and quality of life) that are not measured by the short form-36 [9].

Health-related quality of life is an important indicator to assess health intervention outcomes, inform patient management, and policy development [5]. Assessing HRQoL become an integral part of treatment follow-up and provides valuable feedback about the effectiveness of therapeutic interventions [10], identify the need for health services improvements, and investigate factors predicting well-being. Since highly active antiretroviral treatment (HAART), HRQoL measurement in HIV/AIDS has advanced rapidly to evaluate the effectiveness of treatment and intervention programs [5].

Various kinds of literature across the world indicated that social problems such as stigma, poverty, depression, substance abuse, and cultural beliefs [11], socio-demographic characteristics [12–14], socioeconomic characteristics [12–15], presence of comorbidities [16], stage of the disease, psychological [17], and clinical factors [13, 14] can affect the HRQoL of patients with HIV/AIDS. Moreover, injection drug use [13], alcohol drinking [11], depression [18], and spiritual belief on their disease and medication had also an effect on the mental and physical health of HRQoL [17, 19]. Although the HRQoL of patients has significantly improved after treatment with HAART [1], drug-related side effects [14], poor adherence to HAART [11], and irregular medical follow-up compromised HRQoL [12].

The HIV/AIDS pandemic is the most important and urgent public health challenge facing governments and civil societies around the world [20]. The psychological, social, and
economic burden of the disease associated with its chronicity made the HRQoL of the patients uncertain [11]. The MOS-HIV health survey consisted of a culturally adapted questionnaire [18]. All the items in the general health perception, pain, mental health, and energy dimensions are similar to the generic questionnaire of short form-36, but the rest 6 dimensions were different [6]. HRQoL of people living with HIV remains under-researched in Africa and particularly Ethiopia, yet it is an important health metric; no study was conducted on the HRQoL of adults with HIV from Dessie. Therefore, this study aimed to examine the status of HRQoL and associated factors among people living with HIV/AIDS on HAART in North-East Ethiopia.

Materials and methods
Study area and period
This study was conducted from March 2018 to April 2018 at the Dessie Referral Hospital, Dessie town, Amhara National Regional State, North-East Ethiopia. Dessie is located in the South Wollo zone, 401 kilometers away from Addis Ababa. Dessie is one of the oldest cities in the country preferred to medical tourism and a center for trade. Dessie Referral Hospital is serving the populations of Dessie town (219,978) and the surrounding population (7 million). The hospital has different units. During the study period, 6258 peoples living with HIV were on regular follow-up at the HIV comprehensive care clinic.

Study design
The institutional-based cross-sectional study design was conducted at the HIV comprehensive care clinic of the Dessie Referral Hospital.

Study population
Participants living with HIV/AIDS on HAART who have periodic regular follow-ups in the ART clinic were the study population.

Inclusion and exclusion criteria
Participants whose age 18 and greater and who were willing to give consent were included. Patients who were unable to hear, participants who were on HAART for less than 6 months, and those without updated CD4 records were excluded.

Sample size determination and sampling procedure
The sample size was determined by using a single proportion formula using 73% good HRQoL [21], 95% confidence level, 5% tolerable sampling error, and a 10% non-response rate. There were 6258 registered patients, the sample size was adjusted, and finally, 251 participants were included in this study. On average, the HIV comprehensive care clinic offers services for 70 patients per day. Systematic random sampling was used to select the study participants. The total number of patients who visited the ART comprehensive clinic was taken from the registration book and divided by the total sample size to get the interval. So, the questionnaires were given for every interval. Participants who refused to participate were taken as non-respondents.
Data collection
Data were collected by face-to-face interviews. Data for the outcome variable was collected by one experienced pharmacist. Clinical variables were collected by reviewing the patient’s medical records. Moreover, socio-demographic characteristics and social support-related variables were the data collected other than the use of the MOS-HIV questionnaire using a face-to-face interview. The principal investigators coordinated data collection.

Outcome variable
Data were collected using the MOS-HIV questionnaire [4]. The questionnaire was translated into Amharic and then back-translated to English to check message consistency. Two pharmacy professionals from Wollo University did the forward translation from the English language to the Amharic language. Then, the Amharic version of the questionnaire was sent to other pharmacy professionals, who translate it back to the English language. Finally, the researchers compared the original questionnaire to the back-translated questionnaire. The discrepancy was categorized as minor (wording issues) and major (change in the meaning of questionnaire) and resolved through discussion among the two translating groups.

The outcome variable of the study was the HRQoL of people living with HIV/AIDS on HAART. The HRQoL was assessed using the MOS-HIV health survey which contains 35 questions in 10 dimensions, including general health perceptions, physical functioning, role functioning, pain, social functioning, mental health, energy, health distress, cognitive functioning, and quality of life. One additional item assessed health transition. The subscales of the MOS-HIV are scored as summated rating scales on a 0–100, with higher values indicating better HRQoL [22].

Participants rated the extent to which they had experienced each of the 35 items over the past 1 month. The items and scales of the MOS-HIV health survey were scored by item recoding (11 of the 35 items in the survey require recoding item scores), each scale is summed to compute raw scale scores, and raw scale scores are transformed to a 0–100. The scoring was done based on the following formula: Transformation formula = (100/(the top of the range for the sum of the untransformed item scores—the lowest possible score of the untransformed scale)) × (domain raw score—the lowest possible score of the untransformed scale). The physical and mental summary score was calculated based on the 10 scale scores in the MOS-HIV health survey. For each scale, a z-score transformation was calculated, the physical and mental summary scores using the scoring coefficients were computed and, multiplied by the scoring coefficients and aggregated. The final summary score was calculated as: physical health summary score = 50 + (physical health summary × 10) and mental health summary score = 50 + (mental health summary × 10). The total mean scores of the items were calculated and dichotomized into poor versus good HRQoL [22].

Independent variables
The predictor variables were socio-demographic characteristics of HIV participants, clinical variables, and social support-related variables.

Socio-demographic variables were collected using questionnaires adapted from literature [21, 23] were sex, age, educational status, marital status, working status, and income. Education was categorized based on their level of enrollment in various levels of educational sectors. Understanding the participants’ chances of having some meaningful day-to-day interactions with people, working status was categorized into private, government, self-employed, and unemployed. Social support-related factors (perceived community discrimination and
perceived social support) were assessed by asking participants about their perceived community discrimination and perceived social support and were categorized as yes or no.

Clinical variables (duration of disease, CD4 at the time of diagnosis, current CD4 level, duration of a treatment, WHO clinical stage at treatment initiation, current WHO stage, comorbid condition, treatment regimen during initiation, current treatment regimen, taking cotrimoxazole prophylaxis, taking isoniazid prophylaxis, and taking therapeutic food) were collected by reviewing the patient’s medical records.

Data management and analysis

All data were examined for completeness and consistency before processing. There were no missing data. Data were entered and analyzed using the Statistical Package for Social Sciences version 20.

There are several methods available for the statistical analysis of MOS-HIV data [22]. Cronbach’s alpha was calculated to determine the internal consistency of the MOS-HIV health survey. Reliability was considered to be good if the α value was >0.7.

Validity was analyzed in terms of construct validity. Principal factor analyses were used to test construct validity. Monte Carlo’s principal component analysis for parallel analyses specifying direct Oblimin and Varimax rotation was conducted to test the presence of similar two-factor structures. An eigenvalue of ≥1 was taken as an acceptable factor loading.

After bivariate logistic regression analyses, multiple linear regressions were computed for variables with a p-value less than 0.25, and variables with a p-value less than 0.05 were taken as statistically significant for the association between predictor variables and HRQoL. Results were presented as B-coefficient, 95% Confidence interval (CI), and p-value.

The assumptions of least square regression (random sampling, linearity, normal distribution, constant variance, and multi-collinearity) were checked. A plot of a graph of observed predicted values was symmetrically distributed. In the multiple linear regression model, the correlation matrix showed that there was no multicollinearity between dependent and independent variables. The low variance inflation factor (<2.1) indicated that the associated independent variable has a lower colinearity with the other variables in the model. Homoscedasticity is assessed by visual inspection of plots of residuals versus predicted values. The error term in the regression also had the same variance in the residual predicted values versus the time series plot. The normal probability plot showed that the error term was normally distributed. Kolmogorov-Smirnov (0.20) and Shapiro-Wilk (0.40) tests were non-significant. The Levene statistic (p-value = 0.21) for homogeneity of variance with a p-value greater than 0.05 was considered as a well-fitting regression model, and the percentage of the variability predicted by the model was explained by the R square (61.7%).

The mean score was used to dichotomized the HRQoL score as good and poor. A mean score value of 55 and above was considered as good HRQoL, and below 55 was classified as a poor HRQoL score.

Ethics approval and consent to participate

The research was approved by the Ethics Review Committee of the Pharmacy Department, Wollo University. Before data collection, pertinent information to study participants was provided. Study participants who participated in the study gave their verbal consent. During the data collection process, the confidentiality of the study participants’ related data was maintained.
Results
Socio-demographic, psychosocial, and clinical characteristics of the study participants

The response rate was 93.62%. Sixteen participants were refused to participate in the study. None of the participants were excluded because of unable to hear, less than 6 months of HAART initiation, and without updated CD4 records. Over half of the study participants (57.9%) were female. The majority was in the age range of 25–45 years (54.9%) and completed secondary education (48.5%). Participants having college-level education or above 63.37(5.63) and self-employed 60.08(13.72) had the highest HRQoL mean score and standard deviation (SD). Being unemployed had the lowest HRQoL mean score and SD 46.82(11.40).

A statistically significant HRQoL mean score was found in univariate analysis for age, educational status, work status and marital status of participants. Participants who were 18–24 (β = −6.48, p < 0.001) and 25–45 years of age (β = −6.80, p < 0.001) were more likely to have lower HRQoL compared to greater than 45 years of age. Participants who were illiterate (β = 12.40, p < 0.001), attended primary education (β = 12.92, p < 0.001) and secondary education (β = 9.39, p < 0.001) were more likely to have better HRQoL compared to those attended college level education and above. Single participants had a better HRQoL (β = 9.15, p < 0.001) than Windowed. Participants who were working in private sector (β = −9.65, p < 0.001), government (β = −9.70, p < 0.001) and their work (β = −13.26, p < 0.001) were more likely to have lower HRQoL (Table 1).

Below half (44.2%) of the participants were lived with HIV/AIDS for more than 10 years. Below half (46.8%) of the participants were taking HAART for 6–10 years. Nearly one-third

| Variable               | Frequency (%) | Mean (SD) | P-value | β(95%CI) |
|------------------------|--------------|-----------|---------|----------|
| Sex                    |              |           |         |          |
| Female                 | 136 (57.9)   | 54.47 (12.35) | 0.58   | 0.87 (-2.31,4.07) |
| Male                   | 99 (42.1)    | 55.35 (12.18) | Ref    | Ref      |
| Age                    |              |           |         |          |
| 18–24                  | 50 (21.3)    | 53.47 (7.26) | 0.006  | -6.48 (-11.07,-1.89) |
| 25–45                  | 129 (54.9)   | 53.15 (13.20) | ≤0.001 | -6.80 (-10.57,-3.02) |
| >45                    | 56 (23.8)    | 59.95 (12.33) | Ref    | Ref      |
| Educational status     |              |           |         |          |
| Illiterate             | 16 (6.8)     | 50.96 (8.87) | ≤0.001 | 12.40 (5.89,18.92) |
| Primary                | 57 (24.3)    | 50.45 (17.23) | ≤0.001 | 12.92 (8.50,17.34) |
| Secondary              | 114 (48.5)   | 53.98 (9.86) | ≤0.001 | 9.39 (5.51,13.27) |
| College and above      | 48 (20.4)    | 63.37 (5.63) | Ref    | Ref      |
| Marital status         |              |           |         |          |
| Single                 | 90 (38.3)    | 50.35 (11.65) | 0.001  | 9.15 (4.18,14.13) |
| Married                | 74 (31.5)    | 59.02 (10.34) | 0.85   | 0.49 (-4.61,5.59) |
| Divorced               | 43 (18.3)    | 53.98 (10.75) | 0.05   | 5.52 (-0.05,11.11) |
| Widowed                | 28 (11.9)    | 59.51 (15.73) | Ref    | Ref      |
| Work status            |              |           |         |          |
| Private work           | 93 (39.6)    | 56.53 (11.72) | ≤0.001 | -9.65 (-14.00,-5.29) |
| Governmental           | 55 (23.4)    | 56.47 (9.46) | ≤0.001 | -9.70 (-13.60,-5.81) |
| Self employed          | 34 (14.5)    | 60.08 (13.72) | ≤0.001 | -13.26 (-18.23,-8.29) |
| Unemployed             | 53 (22.6)    | 46.82 (11.40) | Ref    | Ref      |
| Income                 |              |           |         |          |
| ≤ 1000 birr            | 48 (20.4)    | 54.69 (8.39) | 0.88   | 0.35 (-4.53,5.24) |
| 1001–2000 birr         | 58 (24.7)    | 54.44 (18.33) | 0.85   | 0.42 (-4.24,5.09) |
| 2001–3000 birr         | 78 (33.2)    | 54.95 (11.40) | 0.96   | 0.09 (-4.28,4.47) |
| > 3000 birr            | 51 (21.7)    | 55.05 (7.63) | Ref    | Ref      |

β: Unstandardized coefficient, Ref: Reference group.

https://doi.org/10.1371/journal.pone.0247777.t001
(31.4%) and (14%) had above 500 CD4 during data collection and at the time of diagnosis respectively. Concerning HRQoL mean score, participants with less than the year duration of the disease had the highest (62.84) mean score as compared to prolonged durations. Participants who had 201–350 CD4 at the time of diagnosis ($\beta = -6.64, p = 0.01$) and 351–500 CD4 during data collection ($\beta = 10.07, p < 0.001$) had lower and better HRQoL compared to those who had above 500 CD4 respectively. Participants who had less than year ($\beta = -13.43, p < 0.001$), and 6–10 years of disease duration ($\beta = -14.35, p < 0.001$) were more likely to have lower HRQoL compared to those had for more than 10 years. Participants who were currently at WHO stage II had a lower HRQoL ($\beta = -18.27, p < 0.001$) than WHO stage III. Participants who reported not taking of Cotrimoxazole prophylaxis ($\beta = -9.08, p < 0.001$), Isoniazid prophylaxis ($\beta = -3.70, p < 0.02$), and Therapeutic food ($\beta = -8.87, p < 0.001$) were more likely to have lower HRQoL compared to those taking (Table 2).

**HRQoL of participants on HAART**

The highest HRQoL mean score was found for physical functioning 91.02($\pm18.05$). Cognitive functioning had the lowest HRQoL 35.21($\pm19.78$). Physical functioning (91.02$\pm18.05$) and role functioning (88.08$\pm25.03$) had the highest HRQoL mean score and SD (Table 3). Over one-third (42.6%; 95% CI; 36.2%, 48.9%) of participants on HAART had a good quality of life.

**Psychometric characteristics of the HRQoL measure**

Cronbach’s $\alpha$ value was above the standard for all except role functioning (0.34), general health (0.50), and pain (0.48). The Cronbach’s $\alpha$ value for the overall scale was 0.78. Cronbach’s alpha was not calculated for sub-domains with 1 item (social function, quality of life, and health transition). Monte Carlo’s principal component analysis of parallel analysis of MOS-HIV subscales resulted in the extraction of one factor (general health had Eigenvalue of 3.1). Thus, the analysis of physical or mental health summary scores was not done further.

**Factors associated with overall HRQoL**

In the backward multiple linear regression, age, work status, CD4 at time of diagnosis, current CD4 level, duration of treatment, WHO clinical stage at treatment initiation, and taking Cotrimoxazole prophylaxis were found to have statistically significant associations with mean overall HRQoL. Participants who were 25–45 years of age ($\beta = -3.55, p = 0.02$) were significantly more likely to have lower HRQoL compared to those greater than 45 years of age. Participants who were working in private sector ($\beta = -5.66, p = 0.03$), government ($\beta = -4.29, p = 0.01$) and their work ($\beta = -8.86, p < 0.001$) were more likely to have lower HRQoL than unemployed. Participants who had 100–200 ($\beta = -4.84, p = 0.02$) and 201–350 CD4 at the time of diagnosis ($\beta = -7.45, p < 0.001$) and 351–500 CD4 during data collection ($\beta = 8.34, p < 0.001$) had lower and higher HRQoL compared to those who had above 500 CD4 respectively. Participants who had 6–10 years of disease duration ($\beta = -8.28, p < 0.001$) were more likely to have lower HRQoL compared to those who had for more than 10 years. Participants who were at WHO stage II ($\beta = -4.78, p = 0.01$) and III ($\beta = 3.42, p = 0.04$) during treatment initiation had a lower HRQoL and higher than WHO stage III participants. Participants who reported not taking Cotrimoxazole prophylaxis ($\beta = -5.79, p < 0.001$) were more likely to have lower HRQoL compared to those who take (Table 4).

**Discussion**

This study assessed the HRQoL and associated factors among people living with HIV/AIDS on HAART in North-East Ethiopia using a unidimensional HIV specific measure with acceptable
Table 2. Mean HRQoL score across clinical and psychosocial characteristics of respondents in Dessie referral hospital, 2018.

| Variable                              | Frequency (%) | Mean (SD) | P-value   | β (95%CI)     |
|---------------------------------------|---------------|-----------|-----------|---------------|
| **Duration of disease**               |               |           |           |               |
| < 1 year                              | 10 (4.3)      | 62.84 (5.45) | 0.04      | -8.22 (-16.19,-0.25) |
| 1–5 year                              | 36 (15.3)     | 53.76 (6.45) | 0.72      | 0.84 (-3.81,5.50)   |
| 6–10 year                             | 85 (36.2)     | 54.63 (12.98) | 0.99      | -0.01 (-3.54,3.50) |
| > 10 year                             | 104 (44.2)    | 54.61 (13.44) | Ref       | Ref           |
| **CD4 at the time of diagnosis**      |               |           |           |               |
| ≤100                                  | 12 (5.1)      | 51.33 (9.20) | 0.83      | 0.84 (-7.15,8.85)   |
| 100–200                               | 121 (51.5)    | 53.64 (14.83) | 0.53      | -1.46 (-6.12,3.20)  |
| 201–350                               | 69 (29.4)     | 58.83 (9.41) | 0.01      | -6.64 (-11.67,-1.62) |
| > 500                                 | 33 (14)       | 52.13 (2.42) | Ref       | Ref           |
| **Current CD4 level**                 |               |           |           |               |
| 100–200                               | 18 (7.7)      | 59.93 (6.68) | <0.001    | -13.43 (-20.0,-6.97) |
| 201–350                               | 19 (8.1)      | 49.06 (9.57) | 0.23      | -2.56 (-6.78,1.66)  |
| 351–500                               | 124 (52.8)    | 60.86 (10.82) | <0.001    | -14.35 (-18.36,-10.35) |
| > 500                                 | 74 (31.4)     | 47.54 (11.43) | Ref       | Ref           |
| **Duration of treatment**             |               |           |           |               |
| < 1 year                              | 14 (6)        | 50.40 (5.21) | 0.17      | 7.19 (-3.29,17.67)  |
| 1–5 year                              | 75 (31.9)     | 49.06 (6.63) | 0.12      | -3.50 (-7.95,0.95)  |
| 6–10 year                             | 110 (46.8)    | 50.41 (10.33) | <0.001    | 7.17 (3.88,10.46)   |
| > 10 year                             | 36 (15.3)     | 46.50 (12.76) | Ref       | Ref           |
| **WHO clinical stage at treatment initiation** |     |           |           |               |
| I                                     | 5 (2.1)       | 50.40 (5.21) | 0.17      | 7.19 (-3.29,17.67)  |
| II                                    | 37 (15.7)     | 61.08 (6.63) | 0.12      | -3.50 (-7.95,0.95)  |
| III                                   | 103 (43.8)    | 50.41 (10.33) | <0.001    | 7.17 (3.88,10.46)   |
| VI                                    | 90 (38.4)     | 57.58 (14.36) | Ref       | Ref           |
| **Current WHO stage**                 |               |           |           |               |
| I                                     | 20 (8.5)      | 45.47 (11.31) | 0.02      | 5.50 (10.41,-0.59)  |
| II                                    | 80 (34)       | 63.71 (9.31) | <0.001    | 18.24 (-23.36,-13.11) |
| III                                   | 135 (57.5)    | 50.97 (10.87) | Ref       | Ref           |
| **Comorbid condition**                |               |           |           |               |
| Diabetes mellitus                     | 10 (4.3)      | 63.10 (9.27) | 0.02      | -12.12 (-19.69,-4.55) |
| Hypertension                          | 19 (8.1)      | 48.85 (8.33) | 0.59      | 1.53 (-4.07,7.15)   |
| Epilepsy                              | 6 (2.6)       | 49.03 (2.99) | 0.08      | -3.87 (-8.05,1.29)  |
| Psychosis                             | 13 (5.5)      | 63.89 (4.58) | 0.03      | -10.22 (-16.91,-3.53) |
| No comorbidity                        | 187 (79.5)    | 54.56 (12.75) | Ref       | Ref           |
| **Treatment regimen during initiation**|           |           |           |               |
| Efavirenz based                       | 111 (47.2)    | 61.23 (9.87) | ≤0.001    | -12.11 (-14.86,-9.36) |
| Nevirapine based                      | 124(52.8)     | 49.11 (11.36) | Ref       | Ref           |
| **Current treatment regimen**         |               |           |           |               |
| Efavirenz based                       | 115 (48.9)    | 54.54 (11.97) | 0.71      | 0.58 (-2.57,3.74)   |
| Nevirapine based                      | 120(51.1)     | 55.13 (12.58) | Ref       | Ref           |
| **Cotrimoxazole prophylaxis**         |               |           |           |               |
| No                                    | 134(57)       | 58.74(11.67) | ≤0.001    | -9.08(-12.05,-6.11) |
| Yes                                   | 101(43)       | 49.66(11.09) | Ref       | Ref           |
| **Isoniazid prophylaxis**             |               |           |           |               |
| No                                    | 158(67.2)     | 56.05(12.36) | 0.02      | -3.70 (-7.03,-0.37) |
| Yes                                   | 77 (32.8)     | 52.35 (11.75) | Ref       | Ref           |
| **Therapeutic food**                  |               |           |           |               |
| No                                    | 171(72.8)     | 57.25(11.86) | ≤0.001    | -8.87(-12.23,-5.51) |
| Yes                                   | 64 (27.2)     | 48.38 (10.97) | Ref       | Ref           |
| **Perceived community discrimination**|           |           |           |               |
| No                                    | 90(38.3)      | 52.63(12.43) | 0.03      | 3.57(0.35,6.79)     |
| Yes                                   | 145 (61.7)    | 56.21 (11.99) | Ref       | Ref           |
| **Perceived social support**          |               |           |           |               |
| No                                    | 203(86.4)     | 54.43(11.75) | 0.20      | -10.02(-14.44,-5.60) |
| Yes                                   | 32 (13.6)     | 57.40 (15.07) | Ref       | Ref           |

β: Unstandardized coefficient, Ref: Reference group.

https://doi.org/10.1371/journal.pone.0247777.t002

internal consistency reliability. Age, work status, CD4 at time of diagnosis, current CD4 level, duration of treatment, WHO clinical stage at treatment initiation, and taking Cotrimoxazole prophylaxis were associated with HRQoL among people living with HIV/AIDS on HAART
were associated with HRQoL. The present study revealed that close to half of the participants (43%) had a good QoL.

In this study, we observed that close to half of the participants (43%) had a good QoL. This finding compares with previous findings involving HIV patients on treatment from Ethiopia.

Table 3. HRQoL domains mean score of participants on HAART in Dessie referral hospital, 2018.

| QoL domains (number of items) | Mean (SD) | Minimum (Maximum) | Domains of quality of life |
|-------------------------------|-----------|-------------------|---------------------------|
| General health (5)           | 44.51 (16.62) | 20 (85)        | Poor n (%)                |
| Physical functioning (6)     | 91.02 (18.05)  | 8.33 (99.96)   | Good n (%)                |
| Role functioning (2)         | 88.08 (25.03)  | 0 (100)        |                           |
| Social functioning (1)       | 40.85 (29.8)   | 0 (75)         |                           |
| Cognitive functioning (4)    | 35.21 (19.78)  | 0 (68.75)      |                           |
| Pain (2)                     | 46.89 (16.11)  | 22.22 (77.77)  |                           |
| Mental health (5)            | 47.42 (16.79)  | 20 (75)        |                           |
| Energy/Fatigue (4)           | 47.34 (20.14)  | 18.75 (81.25)  |                           |
| Health distress (4)          | 60.42 (26.83)  | 6.25 (93.37)   |                           |
| Quality of life (1)          | 52.23 (21.37)  | 25 (100)       |                           |
| Health transition (1)        | 49.25 (23.72)  | 0 (100)        |                           |
| Total                        | 54.84 (12.26)  | 32.24 (77.42)  |                           |

Table 4. Factors associated with mean overall HRQoL of participants on HAART in Dessie referral hospital, 2018.

| Variable                              | P-value | B   | 95%CI       |
|---------------------------------------|---------|-----|-------------|
| Age                                   |         |     |             |
| 18–24                                 | 0.46    | -1.52 | -5.63,2.57 |
| 25–45                                 | 0.02    | -3.55 | -6.54,0.55 |
| >45                                   | Ref     | Ref  |             |
| Work status                           |         |     |             |
| Private work                          | 0.03    | -5.66 | -9.43,1.88 |
| Governmental                          | 0.01    | -4.29 | -7.83,0.75 |
| Self employed                         | ≤0.001  | -8.86 | -13.50,4.21|
| Unemployed                            | Ref     | Ref  |             |
| CD4 at the time of diagnosis          |         |     |             |
| ≤100                                  | 0.41    | 2.78  | -3.97,9.54 |
| 100–200                               | 0.02    | -4.84 | -9.04,0.63 |
| 201–350                               | 0.001   | -7.45 | -11.73,3.16|
| >500                                  | Ref     | Ref  |             |
| Current CD4 level                     |         |     |             |
| 100–200                               | 0.27    | 2.58  | -2.08,7.24 |
| 201–350                               | 0.06    | -4.24 | -8.77,0.28 |
| 351–500                               | ≤0.001  | 8.34  | 5.55,11.14 |
| >500                                  | Ref     | Ref  |             |
| Duration of treatment                 |         |     |             |
| <1 year                               | 0.41    | -2.57 | -8.72,3.58 |
| 1–5 year                              | 0.38    | 1.70  | -2.16,5.57 |
| 6–10 year                             | ≤0.001  | -8.28 | -12.51,4.04|
| <10 year                              | Ref     | Ref  |             |
| WHO clinical stage at treatment initiation |     |     |             |
| I                                     | 0.22    | 4.95  | -3.02,12.93|
| II                                    | 0.01    | -4.78 | -8.52,1.04 |
| III                                   | 0.04    | 3.42  | 0.06,6.79  |
| VI                                    | Ref     | Ref  |             |
| Cotrimoxazole prophylaxis             |         |     |             |
| No                                    | ≤0.001  | -5.79 | -8.34,3.25 |
| Yes                                   | Ref     | Ref  |             |

β is unadjusted, n = 235, R square = 61.7%.
The proportion of study participants with good QoL was even higher (>70%) according to other studies from sub-Saharan Africa [26]. However, other studies also reported much lower proportions of participants with good QoL than what we observed [25]. The difference might be due to the variation in the tools used to assess HRQoL among studies and differences in the composition of study subjects.

Various studies reported that the psychological domain (5.99) [27], general health functioning (41.35±10.28) [28], role emotional (41.5±15.1) [29], environment domain (12.9±2.5) [30], and energy (60.6±23.3) [18] had the lowest HRQoL mean score. In Iran, HIV patients had low QoL in all health-related domains [31]. Patients on HAART had also a poorer quality of life in all health-related domains than the general population in the United Kingdom [5]. In this study, the cognitive functioning domain of HRQoL had the lowest mean score of 35.21 (±19.78). The possible explanation for this difference might be due to variation in the tools used to assess QoL and differences in the composition of study participants.

The present study revealed that educational status was not significantly associated with HRQoL. This finding discord with other studies conducted elsewhere in the world. Education was significantly correlated with all domains of HRQoL scores [30], and lower education was responsible for lower HRQoL [13, 25, 26]. Thus, it is not surprising that better educational status will yield good HRQoL as patients who have formal education might have superior knowledge regarding the disease, related opportunistic infections, and the medication, and become adherent [32]. The discrepancy might be attributed to the differences in the study areas and periods, and socio-demographic characteristics across the study populations.

Despite marital status promotes health and longevity, this study found a non-significant association. This is because married individuals may have better social support from their partner and children, while widowed and divorced patients may feel sad and discomfort because of the loss of beloved ones and may feel hopeless. This finding contradicted the studies reporting significant associations [26, 28, 33]. The discrepancy might be attributed to the differences in the study populations. The sex of respondents was also not associated with HRQoL. Even if this was in line with the result of a study done in Ethiopia [26], significant associations were also reported [29, 32, 34]. Differences in the study populations might be the reason for the discrepancy.

Participants who were 25–45 years of age ($\beta = -3.55$, $p = 0.02$) were more likely to have lower HRQoL compared to those greater than 45 years of age. Similarly, the age of participants was significantly associated with psychological health [34] and physical functioning [33]. Upon increasing age, HIV patients are more likely to have a comorbidity, opportunistic infections, and non-adherent to the treatment, which cumulatively reduces their HRQoL [35]. Although the effect of comorbidity on HRQoL was non-significant in this study, having comorbidity was found to be an independent predictor of poor QoL [16, 18, 36, 37]. This is due to the differences in the socio-demographic characteristics of study populations.

In this study, social support had a non-statistically significant effect on HRQoL. However, existing data suggested that social support systems were important predictors of QoL [18, 36, 38] where lack of support from family and good social support were found to be independent predictors of poor [37] and better HRQoL [23, 39]. This might be attributed to the differences in the study populations. Social support will improve the ability to face stress-related health-disease processes, promote health and therapeutic compliance. Better social support will protect against the future enacted and internalized stigma [40].

Although community discrimination does not have a statistically significant effect on HRQoL, HIV patients might treat unjustly and become depressed [41]. Except for the physical domain, a higher level of HIV related discrimination was associated with a lower HRQoL [42]. The discrepancy might be attributed to the differences in the study area. The community
members unfairly and unjustly treat patients based on the myth of causal transmission of HIV and preexisting attitudes. People living with HIV might internalize the discrimination they experience, which seriously affects their lives [43].

This study revealed a significant positive association of cotrimoxazole preventive therapy on the overall HRQoL of HIV participants. Preventive therapy was also reported to affect (β = +8.381, p < 0.05) on physical health and symptoms [44]. Cotrimoxazole is a safe and inexpensive antibiotic used to treat opportunistic infections. It can help to reduce the high early mortality and morbidity rate of HIV infection regardless of HAART status [45].

Given the longevity achievable with current HAART for persons with HIV infection [5, 36], treatment with HAART was associated with better HRQoL [23, 25]. Longer treatment duration was associated with higher HRQoL domains, except for the spiritual and level of independence domains [46], while all dimensions of QoL have significantly improved [1]. However, second-line antiretroviral therapy has been reported to reduce QoL [44]. This might be attributed to the increased pill burden, side effects of medication, and disease progression. Studies also revealed that the advancement of disease was associated with lower HRQoL [42].

The present study was in line with these findings where participants who had 6–10 years of disease duration (β = -8.28, p < 0.001) were more likely to have lower HRQoL compared to those who had more than 10 years. This was due to the fact that patients who spent longer after knowing their HIV status might be reluctant about the disease, medication, and lifestyle.

The present study revealed that participants who had current 351–500 CD4 (β = 8.34, p < 0.001) had higher HRQoL compared to those who had above 500 CD4 respectively. Despite the non-significant association between the level of CD4 and HRQoL was reported in Ireland [18] and Ethiopia [34, 42], a lower CD4 count was revealed as a factor responsible for lower HRQoL [13, 28, 32]. In Ethiopia, the determination of patient CD4 levels will be done every six months. CD4 cells are a strong marker for disease progression, and the possible explanations might be that nearly half (52.8%) of participants had 351 to 500 CD4 count and patients might have initiated HAART at the advanced WHO clinical stage.

The present study limitations were recall bias and social desirability bias as participants were requested to respond based on their life experience in the past one month before the interview, and the cross-sectional nature of the study made them unable to establish cause-and-effect relationships. Besides, the lack of rigorous validation or cultural adaptation of the MOS-HIV in Ethiopia might make it difficult in understanding the questionnaire.

Conclusions

In this study, the HRQoL of many Ethiopian adults living with HIV on HAART from the Dessie area was poor. The lowest mean HRQoL scores were observed in the cognitive functioning domain. Age, work status, CD4 at time of diagnosis, current CD4 level, duration of treatment, WHO clinical stage at treatment initiation, and taking Cotrimoxazole prophylaxis were associated with HRQoL among people living with HIV/AIDS on HAART. Routine assessment and appropriate interventions at each clinic visit will improve the HRQoL of people living with HIV/AIDS.

Supporting information

S1 File. Psychometric characteristics of the HRQoL life measure. (DOCX)

Acknowledgments

The authors would like to acknowledge Wollo University.
Author Contributions

Conceptualization: Solomon Ahmed Mohammed.

Data curation: Minilu Girma Yitafr.

Formal analysis: Solomon Ahmed Mohammed.

Investigation: Minilu Girma Yitafr.

Methodology: Solomon Ahmed Mohammed.

Supervision: Minilu Girma Yitafr, Birhanu Demeke Workneh, Abel Demerew Hailu.

Visualization: Birhanu Demeke Workneh, Abel Demerew Hailu.

Writing – original draft: Solomon Ahmed Mohammed.

Writing – review & editing: Solomon Ahmed Mohammed, Minilu Girma Yitafr, Birhanu Demeke Workneh, Abel Demerew Hailu.

References

1. Degroote S, Vogelaers D, Vandijck DM. What determines health-related quality of life among people living with HIV: an updated review of the literature. Archives of Public Health. 2014 Dec; 72(1):40. https://doi.org/10.1186/2049-3258-72-40 PMID: 25671112

2. UNAIDS. Fact sheet—Latest global and regional statistics on the status of the AIDS epidemic. United Nations Programme on HIV and AIDS.2019. Available at: https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf.

3. UNAIDS. UNAIDS data 2019—UNAIDS Eastern and Southern Africa. United Nations Programme on HIV and AIDS.2019. Available at: http://statis.unaids.org/documents/publications/72-unaids-data-2019. https://doi.org/10.1371/journal.pone.0158767 PMID: 27441648

4. World Health Organization. Measuring quality of life: The World Health Organization quality of life instruments (the WHOQOL-100 and the WHOQOL-BREF). WHOQOL-measuring quality of life. 1997.

5. Gakhar H, Kamali A, Holodniy M. Health-related quality of life assessment after antiretroviral therapy: a review of the literature. Drugs. 2013 May 1; 73(7):651–72. https://doi.org/10.1007/s40265-013-0040-4 PMID: 23591907

6. Ware JE Jr. SF-36 health survey update. Spine. 2000 Dec 15; 25(24):3130–9. Available at: https://clinmedjournals.org/articles/jmdt/jmdt-2-023-figure-1.pdf. https://doi.org/10.1097/00007632-20012150-00008 PMID: 1124729

7. Rand Health Care. 12-Item Short Form Survey (SF-12). Available at: https://www.rand.org/health-care/surveys_tools/mos/12-item-short-form.html.

8. World Health Organization. The world health organization quality of life (WHOQOL)-BREF. World Health Organization; 2004.

9. Liu J, Zhu Y, Qu B. Reliability and validity of the Chinese version of the Medical Outcomes Study HIV Health Survey (MOS-HIV) in people living with HIV/AIDS (PLWHA) in China. Plos one. 2018; 13(7). https://doi.org/10.1371/journal.pone.0201177 PMID: 30044881

10. World Health Organization. Global update on the health sector response to HIV. 2014.

11. Costa TL, Oliveira DC, Gomes AM, Formoz GA. Quality of life and people living with AIDS: relationship with sociodemographic and health aspects. Revista latino-americana de enfermagem. 2014 Aug; 22(4):582–90. https://doi.org/10.1590/0104-1169.3350.2455 PMID: 25296141

12. Tran BX, Nguyen LT, Do CD, Le Nguyen Q, Maher RM. Associations between alcohol use disorders and adherence to antiretroviral treatment and quality of life amongst people living with HIV/AIDS. BMC public health. 2014 Dec; 14(1):27. https://doi.org/10.1186/1471-2458-14-27 PMID: 24411007

13. Rourke SB, Bekele T, Tucker R, Greene S, Sobota M, Koomstra J, et al. Housing characteristics and their influence on health-related quality of life in persons living with HIV in Ontario, Canada: results from the positive spaces, healthy places study. AIDS and Behavior. 2012 Nov 1; 16(8):2361–73. https://doi.org/10.1007/s10461-012-0284-6 PMID: 22903401

14. Campsmith ML, Nakashima AK, Davidson AJ. Self-reported health-related quality of life in persons with HIV infection: results from a multi-site interview project. Health and Quality of life Outcomes. 2003 Dec; 1(1):12.
15. Imam MH, Karim MR, Ferdous C, Akhter S. Health related quality of life among the people living with HIV. Bangladesh Medical Research Council Bulletin. 2011; 37(1):1–6. https://doi.org/10.3329/bmrcb.v37i1.7791 PMID: 21710808

16. Miners A, Phillips A, Kreil N, Rodger A, Speakman A, Fisher M, et al. Health-related quality-of-life of people with HIV in the era of combination antiretroviral treatment: a cross-sectional comparison with the general population. The lancet HIV. 2014 Oct 1; 1(1):e32–40. https://doi.org/10.1016/S2352-3018(14)70018-9 PMID: 26423814

17. Sun W, Wu M, Qu P, Lu C, Wang L. Quality of life of people living with HIV/AIDS under the new epidemic characteristics in China and the associated factors. PloS one. 2013; 8(5). https://doi.org/10.1371/journal.pone.0247777

18. George S, Bergin C, Clarke S, Courtney G, Codd MB. Health-related quality of life and associated factors in people with HIV: an Irish cohort study. Health and quality of life outcomes. 2016 Dec; 14(1):115.

19. Briongos Figuero LS, Bachiller Luque P, Palacios Martín T, Román L, Eiros Bouza JM. Depression and health related quality of life among HIV-infected people. European review for medical and pharmacological sciences. 2011; 15(8):855–62. PMID: 21845794

20. Dewan R, GK I, Jiloh RC. Assessment of quality of life among HIV positive people attending tertiary hospital of Delhi, India. J. Commun. Dis. 2009; 41(2):101–8. PMID: 22010497

21. Ayalew MB, Abdela OA, Solomon A, et al. Quality of life of HIV patients taking antiretroviral treatment in a resource limited setting: A case of University of Gondar comprehensive specialized hospital, Ethiopia. J Basic Clin Pharma October-2018; 9(3):302–307.

22. Wu AW. MOS-HIV health survey users manual. Baltimore, MD: Johns Hopkins University. 1999.

23. Abebe Weldsilase Y, Likka MH, Wakayo T, Gerbaba M. Health-related quality of life and associated factors among women on antiretroviral therapy in health facilities of Jimma Town, Southwest Ethiopia. Advances in Public Health. 2018; 2018. https://doi.org/10.1155/2018/1893562 PMID: 31236422

24. Deribew A, Deribe K, Reda AA, Tesfaye M, Hailmichael Y, Maja T, Colebunders R. Change in quality of life: a follow up study among patients with HIV infection with and without TB in Ethiopia. BMC public health. 2013 Dec 1; 13(1):408.

25. Yaya I, Djalonge P, Patassi AA, Landoh DE, Assindo A, Nambiama A, et al. Health-related quality of life among people living with HIV/AIDS in Togo: individuals and contextual effects. BMC research notes. 2019 Dec 1; 12(1):140. https://doi.org/10.1186/s13104-019-4171-x PMID: 30876448

26. Mb A, Oa A, Solomon A, Adugna D, Siraj N, Js Y, et al. Quality of life of HIV patients taking antiretroviral treatment in a resource limited setting: A case of University of Gondar comprehensive specialized hospital, Ethiopia. Journal of Basic and Clinical Pharmacy. 2018 Nov 22;9(4).

27. Yahaya SS, Olorukooba AA, Yusuf R, Abdulrahman H, Amadu L. Health related quality of life of HIV/AIDS patients on highly active antiretroviral therapy in Ahmadu Bello University Teaching Hospital. International Journal of Infectious Diseases. 2016 Apr 1; 45:271.

28. Braguma J, Mutimura E, Frantz JM. Health-related quality of life and associated factors in adults living with HIV in Rwanda. SAHARA-J: Journal of Social Aspects of HIV/AIDS. 2018; 15(1):110–20. https://doi.org/10.1080/17290376.2018.1520144 PMID: 30200815

29. Dutra BS, Lêdo AP, Lins-Kusterer L, Luz E, Prieto IR, Brites C. Changes health-related quality of life in HIV-infected patients following initiation of antiretroviral therapy: a longitudinal study. Brazilian Journal of Infectious Diseases. 2019 Aug; 23(4):211–7. https://doi.org/10.1016/j.bjid.2019.06.005 PMID: 31344351

30. Ndubuka NO, Lim HJ, Ehlers VJ, Van Der Wal DM. Health-related quality of life of patients on antiretroviral treatment in Botswana: A cross-sectional study. Palliative & supportive care. 2017 Apr; 15(2):214–22.

31. Razavi P, Hajifathalian K, Saeedi B, Esmaeeli Djavid G, Rasoulinejad M, Hajjabolbaghi M, et al. Quality of life among persons with HIV/AIDS in Iran: internal reliability and validity of an international instrument and associated factors. AIDS research and treatment. 2012. https://doi.org/10.1155/2012/849406 PMID: 22292116

32. Arrey AE, Bilsen J, Lacor P, Deschepper R. Spirituality/religiosity: A cultural and psychological resource among Sub-Saharan African migrant women with HIV/AIDS in Belgium. PloS one. 2016; 11(7).

33. Emuren L, Welles S, Evans AA, Polansky M, Okulicz JF, Macalino G, et al. Health-related quality of life among military HIV patients on antiretroviral therapy. PloS one. 2017; 12(6). https://doi.org/10.1371/journal.pone.0178953 PMID: 28591164
35. Jha N, Ravi SP, Anurag M. Effect of an educational intervention on knowledge and perception regarding rational medicine use and self-medication. Journal of Nepal Health Research Council. 2018; 16(3):313–20. PMID: 30455492
36. Basavaraj KH, Navya MA, Rashmi R. Quality of life in HIV/AIDS. Indian journal of sexually transmitted diseases and AIDS. 2010 Jul; 31(2):75. https://doi.org/10.4103/0253-7184.74971 PMID: 21716787
37. Zeleke Negera G, Ayele Mega T. Health-related quality of life among admitted HIV/AIDS patients in selected Ethiopian tertiary care settings: a cross-sectional study. The Open Public Health Journal. 2019 Dec 31;12(1).
38. Den Daas C, van den Berk GE, Kleene MJ, de Munnik ES, Lijmer JG, Brinkman K. Health-related quality of life among adult HIV positive patients: assessing comprehensive themes and interrelated associations. Quality of Life Research. 2019 Oct 1; 28(10):2685–94. https://doi.org/10.1007/s11136-019-02203-y PMID: 31098796
39. Hidru TH, Wang F, Lolokote S, Jia Y, Chen M, Tong W, et al. Associated factors of self-reported psychopathology and health related quality of life among men who have sex with men (MSM) with HIV/AIDS in Dalian, China: a pilot study. Infectious diseases of poverty. 2016 Dec; 5(1):108. https://doi.org/10.1186/s40249-016-0204-z PMID: 27903303
40. Kaplan BH, Cassel JC, Gore S. Social support and health. Medical care. 1977; 15(5):47–58. https://doi.org/10.1097/00005650-197705001-00006 PMID: 853781
41. Burki TK. Discrimination against people with HIV persists in China. The Lancet. 2011; 377(9762):286–7. https://doi.org/10.1016/s0140-6736(11)60079-2 PMID: 21322842
42. Mekuria LA, Sprangers MA, Prins JM, Yalew AW, Nieuwkerk PT. Health-related quality of life of HIV-infected adults receiving combination antiretroviral therapy in Addis Ababa. AIDS care. 2015 Aug 3; 27(8):934–45. https://doi.org/10.1080/09540121.2015.1020748 PMID: 25782603
43. Pascoe EA, Smart Richman L. Perceived discrimination and health: a meta-analytic review. Psychological bulletin. 2009; 135(4):531. https://doi.org/10.1037/a0016059 PMID: 19586161
44. Melaku T, Mamo G, Chelkeba L, Chanie T. Health-Related Quality of Life Among People Living with Human Immunodeficiency Virus on Highly Active Antiretroviral Therapy in Ethiopia: PROQOL-HIV Based Survey. Patient Related Outcome Measures. 2020; 11:73. https://doi.org/10.2147/PROM.S239429 PMID: 32184699
45. Suthar AB, Granich R, Mermin J, Van Rie A. Bulletin of the World health Organization. 2013; 90:128–138c.
46. Alemayeahu M, Wubshet M, Mesfin N, Tamiru A, Gebayeahu A. Health-related quality of life of HIV infected adults with and without Visceral Leishmaniasis in Northwest Ethiopia. Health and quality of life outcomes. 2017 Dec; 15(1):65. https://doi.org/10.1186/s12955-017-0636-6 PMID: 28851361